Session

IBD (Posters)

THE INCREMENTAL RATE OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE COMPARED TO PATIENTS WITHOUT IMMUNE-MEDIATED DISEASES
THE INCREMENTAL RATE OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE COMPARED TO PATIENTS WITHOUT IMMUNE-MEDIATED DISEASES

IBD (Posters)  et al.

NOVEL SERUM SOLUBLE MARKERS OF HISTOLOGICAL HEALING IN ULCERATIVE COLITIS
NOVEL SERUM SOLUBLE MARKERS OF HISTOLOGICAL HEALING IN ULCERATIVE COLITIS

IBD (Posters)  et al.

DEGREE OF HISTOLOGICAL ACTIVITY IS NOT ASSOCIATED WITH VEDOLIZUMAB THERAPY OUTCOME IN ULCERATIVE COLITIS
DEGREE OF HISTOLOGICAL ACTIVITY IS NOT ASSOCIATED WITH VEDOLIZUMAB THERAPY OUTCOME IN ULCERATIVE COLITIS

IBD (Posters)  et al.

EFFICACY AND SECURITY OF USTEKINUMAB: OUR EXPERIENCE
EFFICACY AND SECURITY OF USTEKINUMAB: OUR EXPERIENCE

IBD (Posters)  et al.

EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB
EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB

IBD (Posters)  et al.

ANTI-DRUG ANTIBODIES DETECTED IN THE PRESENCE OF ADEQUATE INFLIXIMAB DRUG LEVELS IN IBD PATIENTS IN CLINICAL REMISSION HAVE LIMITED CLINICAL SIGNIFICANCE
ANTI-DRUG ANTIBODIES DETECTED IN THE PRESENCE OF ADEQUATE INFLIXIMAB DRUG LEVELS IN IBD PATIENTS IN CLINICAL REMISSION HAVE LIMITED CLINICAL SIGNIFICANCE

IBD (Posters)  et al.

INVESTIGATING THE ASSOCIATIONS BETWEEN PATIENT REPORTED OUTCOMES AND FAECAL CALPROTECTIN IN ULCERATIVE COLITIS: THE DISCORDANCE BETWEEN 'GUT FEELING' AND IBD -'CONTROL'
INVESTIGATING THE ASSOCIATIONS BETWEEN PATIENT REPORTED OUTCOMES AND FAECAL CALPROTECTIN IN ULCERATIVE COLITIS: THE DISCORDANCE BETWEEN 'GUT FEELING' AND IBD -'CONTROL'

IBD (Posters)  et al.

COST EFFECTIVENESS OF A PROACTIVE THERAPEUTIC DRUG MONITORING STRATEGY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB
COST EFFECTIVENESS OF A PROACTIVE THERAPEUTIC DRUG MONITORING STRATEGY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING INFLIXIMAB

IBD (Posters)  et al.

IMMUNOSUPPRESSANT MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE: A REVIEW OF SERIOUS ADVERSE EVENTS
IMMUNOSUPPRESSANT MAINTENANCE THERAPY IN INFLAMMATORY BOWEL DISEASE: A REVIEW OF SERIOUS ADVERSE EVENTS

IBD (Posters)  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

IBD (Posters)  et al.

EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL
EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

IBD (Posters)  et al.

SUBOPTIMAL VACCINATION ADHERENCE IN MOTHERS WITH INFLAMMATORY BOWEL DISEASE AND THEIR BIOLOGIC EXPOSED INFANTS
SUBOPTIMAL VACCINATION ADHERENCE IN MOTHERS WITH INFLAMMATORY BOWEL DISEASE AND THEIR BIOLOGIC EXPOSED INFANTS

IBD (Posters)  et al.

ANXIETY, DEPRESSION AND ALEXITHYMIC TRAITS IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS: CORRELATIONS WITH CLINICAL SYMPTOMS AND INFLAMMATION INDICES
ANXIETY, DEPRESSION AND ALEXITHYMIC TRAITS IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS: CORRELATIONS WITH CLINICAL SYMPTOMS AND INFLAMMATION INDICES

IBD (Posters)  et al.

CROHN'S DISEASE EXCLUSION DIET INDUCES REMISSION IN ADULTS WITH MILD TO MODERATE CROHN´S DISEASE: PRELIMINARY REPORT FROM A RANDOMISED CONTROLLED TRIAL (CDED-AD TRIAL)
CROHN'S DISEASE EXCLUSION DIET INDUCES REMISSION IN ADULTS WITH MILD TO MODERATE CROHN´S DISEASE: PRELIMINARY REPORT FROM A RANDOMISED CONTROLLED TRIAL (CDED-AD TRIAL)

IBD (Posters)  et al.

THE PRESENCE OF CITRATE IN ADALIMUMAB-BASED TREATMENTS CORRELATES WITH THE PERCEPTION OF PAIN AFTER SUBCUTANEOUS INJECTION, IN INFLAMMATORY BOWEL DISEASE PATIENTS
THE PRESENCE OF CITRATE IN ADALIMUMAB-BASED TREATMENTS CORRELATES WITH THE PERCEPTION OF PAIN AFTER SUBCUTANEOUS INJECTION, IN INFLAMMATORY BOWEL DISEASE PATIENTS

IBD (Posters)  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX REMODELLING ARE ASSOCIATED WITH INTESTINAL FIBROSIS ASSESSED BY MAGNETIC RESONANCE ENTEROGRAPHY AND ACCUMULATED INTESTINAL DAMAGE (LÉMANN INDEX) - THE IBSEN STUDY
BIOMARKERS OF EXTRACELLULAR MATRIX REMODELLING ARE ASSOCIATED WITH INTESTINAL FIBROSIS ASSESSED BY MAGNETIC RESONANCE ENTEROGRAPHY AND ACCUMULATED INTESTINAL DAMAGE (LÉMANN INDEX) - THE IBSEN STUDY

IBD (Posters)  et al.

ROLE OF IFN?-ACTIVATED MACROPHAGES IN THE EPITHELIAL MESENCHYMAL TRANSITION IN CROHN'S DISEASE
ROLE OF IFN?-ACTIVATED MACROPHAGES IN THE EPITHELIAL MESENCHYMAL TRANSITION IN CROHN'S DISEASE

IBD (Posters)  et al.

BIOMARKERS OF ELASTIN DEGRADATION IS ASSOCIATED WITH CLINICAL AND BIOCHEMICALLY ACTIVE DISEASE IN CROHN'S DISEASE
BIOMARKERS OF ELASTIN DEGRADATION IS ASSOCIATED WITH CLINICAL AND BIOCHEMICALLY ACTIVE DISEASE IN CROHN'S DISEASE

IBD (Posters)  et al.

PHYSICAL EXERCISE IS ASSOCIATED WITH BETTER BODY COMPOSITION TRAITS IN YOUNG ADULTS WITH CHILDHOOD-ONSET INFLAMMATORY BOWEL DISEASE
PHYSICAL EXERCISE IS ASSOCIATED WITH BETTER BODY COMPOSITION TRAITS IN YOUNG ADULTS WITH CHILDHOOD-ONSET INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

RAC1/PSTAT3 EXPRESSION IN LYMPHOCYTES MAY SERVE AS A PHARMACODYNAMIC MARKER TO OPTIMIZE PERSONALIZED THIOPURINE THERAPY IN IBD PATIENTS
RAC1/PSTAT3 EXPRESSION IN LYMPHOCYTES MAY SERVE AS A PHARMACODYNAMIC MARKER TO OPTIMIZE PERSONALIZED THIOPURINE THERAPY IN IBD PATIENTS

IBD (Posters)  et al.

Item 121 - 140 / 279
1 2 3 4 5 6
7
8 9 10 11 12 13 14